ライフサイエンスコーパス: Sm-EDTMP

1 (153)Sm-EDTMP was administered to the treatment group at 37 M

2 (153)Sm-EDTMP with PBPC support can provide bone-specific the

3 doses (range, one to 13 doses) and 2.9 (153)Sm-EDTMP doses (range, one to six doses).

4 diamine tetramethylene phosphonic acid ((153)Sm-EDTMP) therapy for osteosarcoma is being investigated

5 ediaminetetramethylene phosphonic acid ((153)Sm-EDTMP), (179m)SnCl, and (166)Ho-Labeled 1,4,7,10-tetr

6 re obtained at 4 and 48 h or 72 h after (153)Sm-EDTMP therapy for 3D-RD analysis.

7 BPC or marrow infusion on day +14 after (153)Sm-EDTMP, recovery of hematopoiesis was problematic in t

8 At day +13 after (153)Sm-EDTMP, residual whole-body radioactivity was 1% to 65

9 ted with the endoradiotherapeutic agent (153)Sm-EDTMP.

10 Docetaxel and (153)Sm-EDTMP can be combined safely at full doses over repea

11 1 and 22 (and day 43 for cohort 6), and (153)Sm-EDTMP was administered on day -1 to 1 of each cycle.

12 ll discuss the beta emitters (89)Sr and (153)Sm-EDTMP.

13 Hematologic toxicity at 30 mCi (153)Sm-EDTMP/kg requires PBPC grafts with more than 2 x 10(6

14 Patients received a low dose of (153)Sm-EDTMP (37.0-51.8 MBq/kg), followed on hematologic rec

15 his study, we analyzed the influence of (153)Sm-EDTMP administered activity (AA), osteosarcoma tumor

16 lt of the intravenous administration of (153)Sm-EDTMP at the dose studied.

17 Because the dose-limiting toxicity of (153)Sm-EDTMP is thrombocytopenia, a dose-escalation trial us

18 ffects of intravenous administration of (153)Sm-EDTMP on the developing physeal and articular cartila

19 ed in a phase I or II clinical trial of (153)Sm-EDTMP were analyzed using the 3-dimensional radiobiol

20 ose were linear with injected amount of (153)Sm-EDTMP.

21 h 1, 3, 4.5, 6, 12, 19, or 30 mCi/kg of (153)Sm-EDTMP.

22 sing an every-6-week dosing schedule of (153)Sm-EDTMP.

23 ylenediaminetetramethylene phosphonate ((153)Sm-EDTMP) is an effective component of multimodality the

24 ene diamine tetramethylene phosphonate ((153)Sm-EDTMP), a bone-seeking radiopharmaceutical, provides

25 Therefore, (153)Sm-EDTMP may prove to be an integral component of therap

26 is a bone-seeking radionuclide, whereas (153)Sm-EDTMP is a bone-seeking tetraphosphonate; both have b

27 Thirty patients were treated with (153)Sm-EDTMP.

28 myeloma cells exposed to both PS-341 and 153-Sm-EDTMP.

29 /kg), 1 day prior to and 1 day following 153-Sm-EDTMP (22.5 MBq) showed a significantly prolonged med

30 g), or a single nonmyeloablative dose of 153-Sm-EDTMP (22.5 MBq) were 21, 22, and 28 days, respective

31 ated with the combination of PS-341 plus 153-Sm-EDTMP.

32 S-341 with the bone-seeking radionuclide 153-Sm-EDTMP.

33 not differ between animals treated with 153-Sm-EDTMP alone versus those treated with the combination